Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

Neurology

Volumn 82, Issue 20, 2014, Pages 1791-1797

  Marek, Kenneth ^a   Seibyl, John ^a   Eberly, Shirley ^b   Oakes, David ^b   Shoulson, Ira ^c   Lang, Anthony E ^d   Hyson, Chris ^e   Jennings, Danna ^a  

^a Center for Neurodegenerative and Vascular Brain Disorders   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CARBOMETHOXY 3 BETA(4 IODOPHENYL)TROPANE I 123; CEP 1347; DOPAMINE TRANSPORTER; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; ANTIPARKINSON AGENTS; BRAIN; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84902205243     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000424     Document Type: Article

References (23)

1. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
2. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
3. Parkinson Study Group. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-1490.
4. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET Study. Ann Neurol 2003;54:93-101.
5. Marek K, Seibyl J; Parkinson Study Group. β-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-CIT Study: long-term imaging assessment. Neurology 2003;60(suppl 1):A298.
6. Seibyl JP, Marek K, Quinlan D, et al. Decreased singlephoton emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
7. Seibyl JP. Single-photon emission computed tomography of the dopamine transporter in parkinsonism. J Neuroimaging 1999;9:223-228.
8. Jennings D, Seibyl JP, Oakes D, et al. [123I]β-CIT and SPECT imaging versus clinical evaluation in parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004;61:1219-1228.
9. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002;10:36-43.
10. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003; 18:1415-1423.
11. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000;55:1540-1547.
12. Scherfler C, Schwarz J, Antonini A, et al. Role of DATSPECT in the diagnostic work up of parkinsonism. Mov Disord 2007;22:1229-1238.
13. Varrone A, Marek KL, Jennings D, et al. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1023-1032.
14. Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-2094.
15. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591.
16. Nurmi E, Ruottinen HM, Kaasinen V, et al. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 2000;47:804-808.
17. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-1943.
18. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
19. The NINDS NET-PD Investigators. A randomized, doubleblind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-671.
20. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007;22:2210-2215.
21. Bajaj NP, Gontu V, Birchall J, et al. Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. J Neurol Neurosurg Psychiatry 2010;81:1223-1228.
22. The GPI 1485 Investigators. GPI 1485, a neuroimmunophilin ligand, fails to alter disease progression in mild to moderate Parkinson's disease. Mov Disord 2006;21:S607.
23. Booij J, Bergmans P, Winogrodzka A, et al. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse 2001;39:101-108.